Update on prostate brachytherapy: Long-term outcomes and treatment-related morbidity

Current Urology Reports

Volumn 12, Issue 3, 2011, Pages 237-242

  Kao, Johnny ^a   Cesaretti, Jamie A ^b   Stone, Nelson N ^c   Stock, Richard G ^c  

^a Florida Radiation Oncology Group   (United States)

^b Florida Radiation Oncology Group   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Prostate cancer; Quality of life; Seed implantation

Indexed keywords

CESIUM 131; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OUTCOME ASSESSMENT; PROSTATE CANCER; RADIATION DOSE; RECURRENT CANCER; SURGICAL TECHNIQUE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT PLANNING;

BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955856281     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-011-0183-3     Document Type: Article

References (50)

1. J Mohler RR Bahnson B Boston, et al. 2010 NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 162 200 20141676 1:CAS:528:DC%2BC3cXjt1Wlt7k%3D
2. PC Walsh TL DeWeese MA Eisenberger 2007 Clinical practice. Localized prostate cancer N Engl J Med 357 2696 2705 18160689 10.1056/NEJMcp0706784 1:CAS:528:DC%2BD1cXisVOnsQ%3D%3D
3. RG Stock NN Stone 2010 Current topics in the treatment of prostate cancer with low-dose-rate brachytherapy Urol Clin North Am 37 83 96 20152522 10.1016/j.ucl.2009.11.013 Table of Contents
4. Timmerman RD, Xing L. Image-guided and adaptive radiation therapy. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2010.
5. HH Holm N Juul JF Pedersen, et al. 1983 Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography J Urol 130 283 286 6876274 1:STN:280:DyaL3s3mvVymuw%3D%3D (Pubitemid 13037600)
6. RG Stock NN Stone MF Wesson JK DeWyngaert 1995 A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation Int J Radiat Oncol Biol Phys 32 219 225 7721619 1:STN:280:DyaK2M3jvVWruw%3D%3D
7. Sylvester JE, Grimm PD, Wong J, et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following i(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2010 [Epub ahead of print].
8. DR Reed KE Wallner GS Merrick, et al. 2007 A prospective randomized comparison of stranded vs. Loose 125i seeds for prostate brachytherapy Brachytherapy 6 129 134 17434106 10.1016/j.brachy.2007.01.003 (Pubitemid 46551962)
9. MK Murphy RK Piper LR Greenwood, et al. 2004 Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy Med Phys 31 1529 1538 15259657 10.1118/1.1755182 1:CAS:528:DC%2BD2cXltlOru7k%3D (Pubitemid 38808522)
10. JJ Tomaszewski MC Smaldone S Makaroun, et al. 2010 Cesium 131 versus iodine 125 implants for prostate cancer: evaluation of early psa response Can J Urol 17 5360 5364 20974027
11. SJ Frank RJ Stafford JA Bankson, et al. 2008 A novel MRI marker for prostate brachytherapy Int J Radiat Oncol Biol Phys 71 5 8 18406882 10.1016/j.ijrobp.2008.01.028 (Pubitemid 351491423)
12. J Adam Cunha IC Hsu J Pouliot, et al. 2010 Toward adaptive stereotactic robotic brachytherapy for prostate cancer: demonstration of an adaptive workflow incorporating inverse planning and an MR stealth robot Minim Invasive Ther Allied Technol 19 189 202 20642386 10.3109/13645706.2010.497000
13. WR Lee AF deGuzman RL Bare, et al. 2000 Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution Int J Radiat Oncol Biol Phys 46 83 88 10656377 10.1016/S0360-3016(99)00359-4 1:STN:280: DC%2BD3c7itVWksg%3D%3D (Pubitemid 30021484)
14. L Potters E Calugaru A Jassal J Presser 2006 Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy? Int J Radiat Oncol Biol Phys 65 1014 1019 16682144 10.1016/j.ijrobp.2006.02.003
15. TJ Wilt R MacDonald I Rutks, et al. 2008 Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer Ann Intern Med 148 435 448 18252677 (Pubitemid 351665443)
16. Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2010 [Epub ahead of print].
17. NN Stone MM Stone BS Rosenstein, et al. 2011 Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy J Urol 185 495 500 21167528 10.1016/j.juro.2010.09.099
18. L Potters C Morgenstern E Calugaru, et al. 2008 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer J Urol 179 S20 S24 18405743 10.1016/j.juro.2008.03.133 (Pubitemid 351492525)
19. AV D'Amico R Whittington SB Malkowicz, et al. 1998 Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 969 974 9749478 10.1001/jama.280.11.969 (Pubitemid 28445094)
20. RG Stock JA Cesaretti NN Stone 2006 Disease-specific survival following the brachytherapy management of prostate cancer Int J Radiat Oncol Biol Phys 64 810 816 16309852 10.1016/j.ijrobp.2005.09.005 (Pubitemid 43183579)
21. RG Stock JA Cesaretti P Unger NN Stone 2008 Distant and local recurrence in patients with biochemical failure after prostate brachytherapy Brachytherapy 7 217 222 18635024 10.1016/j.brachy.2008.04.002 (Pubitemid 351957935)
22. DA Ahove KE Hoffman JC Hu, et al. 2010 Which patients with undetectable psa levels 5 years after radical prostatectomy are still at risk of recurrence?-implications for a risk-adapted follow-up strategy Urology 76 1201 1205 20709376 10.1016/j.urology.2010.03.092 This is an important retrospective study describing the risk of late biochemical failure in patients treated with radical prostatectomy.
23. S Jabbari VK Weinberg K Shinohara, et al. 2010 Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost Int J Radiat Oncol Biol Phys 76 36 42 19409729 10.1016/j.ijrobp.2009.01.029 1:CAS:528:DC%2BD1MXhsFGru7vP
24. B Pickett J Kurhanewicz J Pouliot, et al. 2006 Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level Int J Radiat Oncol Biol Phys 65 65 72 16517094 10.1016/j.ijrobp.2005.11.037 1:CAS:528: DC%2BD28Xjs1GlsLg%3D
25. LS Wilson R Tesoro EP Elkin, et al. 2007 Cumulative cost pattern comparison of prostate cancer treatments Cancer 109 518 527 17186528 10.1002/cncr.22433 (Pubitemid 46190959)
26. A Konski W Speier A Hanlon JR Beck A Pollack 2007 Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 25 3603 3608 17704408 10.1200/JCO.2006.09.0811 (Pubitemid 47372597)
27. JW Robinson S Moritz T Fung 2002 Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma Int J Radiat Oncol Biol Phys 54 1063 1068 12419432 10.1016/S0360-3016(02)03030-4 (Pubitemid 35292617)
28. MG Sanda RL Dunn J Michalski, et al. 2008 Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 1250 1261 18354103 10.1056/NEJMoa074311 1:CAS:528:DC%2BD1cXjvVWmtrc%3D This large prospective quality-of-life analysis demonstrated that although patients in the prostatectomy group were younger and had a higher baseline sexual function score, surgically treated patients had a much larger decline in sexual function at 2 years than patients treated with brachytherapy or EBRT. (Pubitemid 351439226)
29. Y Pardo F Guedea F Aguilo, et al. 2010 Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment J Clin Oncol 28 4687 4696 20921463 10.1200/JCO.2009.25.3245
30. JL Gore L Kwan SP Lee RE Reiter MS Litwin 2009 Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer J Natl Cancer Inst 101 888 892 19509365 10.1093/jnci/djp114
31. AB Jani S Hellman 2003 Early prostate cancer: clinical decision-making Lancet 361 1045 1053 12660074 10.1016/S0140-6736(03)12833-4 (Pubitemid 36351377)
32. DA Kuban SL Tucker L Dong, et al. 2008 Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 67 74 17765406 10.1016/j.ijrobp.2007.06.054 (Pubitemid 350251041)
33. AL Zietman K Bae JD Slater, et al. 2010 Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09 J Clin Oncol 28 1106 1111 20124169 10.1200/JCO.2009.25.8475
34. L Kestin N Goldstein F Vicini, et al. 2002 Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54 686 697 12377319 10.1016/S0360-3016(02)03011-0
35. BJ Davis TM Pisansky TM Wilson, et al. 1999 The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy Cancer 85 2630 2637 10375112 10.1002/(SICI)1097-0142(19990615)85: 12<2630::AID-CNCR20>3.0.CO;2-L 1:STN:280:DyaK1MzgtFKnug%3D%3D (Pubitemid 29272750)
36. J Crook N Patil C Ma M McLean J Borg 2010 Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy Int J Radiat Oncol Biol Phys 77 1079 1084 19879700 10.1016/j.ijrobp.2009.06.040
37. AY Ho RJ Burri GT Jennings, et al. 2007 Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103pd implantation and external beam radiation for t3c prostate cancer Brachytherapy 6 38 43 17284384 10.1016/j.brachy.2006.09.003 (Pubitemid 46187325)
38. JR Sathya IR Davis JA Julian, et al. 2005 Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate J Clin Oncol 23 1192 1199 15718316 10.1200/JCO.2005.06.154 This North American randomized trial demonstrated improved biochemical control with combined brachytherapy and EBRT compared to EBRT alone. However, because this study was relatively small, the external-beam dose in the control arm was suboptimal and high-dose rate brachytherapy boost was used rather than the more widely used approach of radioactive seed implant, this study is not widely cited in the brachytherapy literature. (Pubitemid 46202276)
39. PJ Hoskin K Motohashi P Bownes L Bryant P Ostler 2007 High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial Radiother Oncol 84 114 120 17531335 10.1016/j.radonc.2007.04.011 (Pubitemid 47284526)
40. RG Stock NN Stone A Tabert C Iannuzzi JK DeWyngaert 1998 A dose-response study for i-125 prostate implants Int J Radiat Oncol Biol Phys 41 101 108 9588923 10.1016/S0360-3016(98)00006-6 1:STN:280:DyaK1c3kvVegtQ%3D%3D (Pubitemid 28211308)
41. J Kao NN Stone A Lavaf, et al. 2008 (125)i monotherapy using d90 implant doses of 180 gy or greater Int J Radiat Oncol Biol Phys 70 96 101 17980505 10.1016/j.ijrobp.2007.06.067 1:CAS:528:DC%2BD2sXhsVentr3O (Pubitemid 350251042)
42. AY Ho RJ Burri JA Cesaretti NN Stone RG Stock 2009 Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 75 16 22 19289266 10.1016/j.ijrobp.2008.10.071 1:CAS:528:DC%2BD1MXhtVegsLjP
43. RG Stock NN Stone JA Cesaretti BS Rosenstein 2006 Biologically effective dose values for prostate brachytherapy: effects on psa failure and posttreatment biopsy results Int J Radiat Oncol Biol Phys 64 527 533 16242258 10.1016/j.ijrobp.2005.07.981 (Pubitemid 43083442)
44. RG Stock S Yalamanchi SJ Hall NN Stone 2010 Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation J Urol 183 546 550 20006854 10.1016/j.juro.2009.10.006 1:CAS:528:DC%2BC3cXitVSrtL0%3D
45. N Bittner GS Merrick KE Wallner, et al. 2010 Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer? Int J Radiat Oncol Biol Phys 76 1078 1084 19553031 10.1016/j.ijrobp.2009.02.069
46. A Widmark O Klepp A Solberg, et al. 2009 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (spcg-7/sfuo-3): an open randomised phaseIII trial Lancet 373 301 308 19091394 10.1016/S0140- 6736(08)61815-2 1:CAS:528:DC%2BD1MXhtVaqs7g%3D
47. Carpenter TJ, Forsythe K, Kao J, Stone NN, Stock RG. Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy 2010 [Epub ahead of print].
48. AV D'Amico BJ Moran MH Braccioforte, et al. 2009 Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease J Clin Oncol 27 3923 3928 19597029 10.1200/JCO.2008.20.3992
49. RJ Burri NN Stone P Unger RG Stock 2010 Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 77 1338 1344 20138442 10.1016/j.ijrobp. 2009.06.061
50. PL Nguyen AV D'Amico AK Lee WW Suh 2007 Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature Cancer 110 1417 1428 17694553 10.1002/cncr.22941 (Pubitemid 47463054)